ArticleNature communications2026
Catalytic hybrid solvent regeneration in membrane vacuum processes for direct air capture.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct Air Capture is a promising climate mitigation technology, but its deployment is limited by high energy demand. This study improves the energy efficiency and sustainability of liquid-based Direct Air Capture by integrating catalytic solvent regeneration and hybrid solvents with a low-temperature membrane vacuum regeneration process. Iron-sulfated zirconia catalysts supported on alumina and silica are synthesized and evaluated, with silica exhibiting superior catalytic performance. An optimal iron-sulfated zirconia to silica ratio of 1:1 reduces relative heat duty by up to 59.7% in the membrane vacuum system. To assess the impact of hybrid solvents on energy consumption, a solvent composed of 3 molar potassium taurinate and 1 molar potassium sarcosinate achieves a 69.1% improvement in CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.